Self-esteem in patients with inflammatory bowel disease
- PMID: 32144613
- PMCID: PMC7295843
- DOI: 10.1007/s11136-020-02467-9
Self-esteem in patients with inflammatory bowel disease
Abstract
Purpose: The purpose of this study was to explore self-esteem and associations between self-esteem and sociodemographic, clinical, and psychological factors in patients with inflammatory bowel disease (IBD), a disease of chronic relapsing inflammation of the gastrointestinal tract. IBD symptoms, including pain, fatigue, and diarrhea, as well as potential life-long medical treatment and surgery, may be demanding, cause significant challenges, and influence self-esteem.
Methods: In this cross-sectional multicenter study, participants were recruited from nine hospitals in the southeastern and western regions of Norway from March 2013 to April 2014. Data were collected using self-report questionnaires. Self-esteem was assessed by the Rosenberg Self-Esteem Scale, fatigue was assessed by the Fatigue Questionnaire, self-efficacy was assessed by the General Self-Efficacy Scale, and disease activity was assessed by the Simple Clinical Colitis Activity Index for ulcerative colitis (UC) and Harvey Bradshaw Index for Crohn's disease (CD). Multiple linear regression analysis was applied to examine associations between self-esteem and sociodemographic, clinical, and psychological factors.
Results: In total, 411 of 452 (91%) patients had evaluable data and were included in this study. The mean scores on self-esteem, self-efficacy, total fatigue, anxiety, and depression were similar between UC patients and CD patients. Male gender, being employed, and higher self-efficacy were independently associated with higher self-esteem, whereas anxiety and depression were independently associated with lower self-esteem. Neither disease activity nor fatigue were associated with self-esteem in the final multiple regression analyses.
Conclusion: Patient-centered interventions that improve self-esteem and reduce anxiety and depression seem to be important to optimize IBD management.
Keywords: Chronic disease; Coping; Crohn’s disease; Health psychology; Health-related quality of life; Inflammatory bowel disease; Self-efficacy; Self-esteem; Ulcerative colitis.
Conflict of interest statement
Jahnsen Jørgen has served as a speaker, consultant, or advisory board member for AbbVie, Astro Pharma, Boerhinger Ingelheim, BMS, Celltrion, Ferring, Hikma, Janssen, Meda, MSD, Napp Pharma, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts, and Sandoz. Grimstad Tore has served as a speaker for Ferring Pharmaceuticals and Takeda, and advisory boardmember for Takeda, Janssen-Cilag, and Tillotts. Jelsness-Jørgensen Lars-Petter has received an advisory board honorarium from Takeda Pharmaceuticals.
References
-
- Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with inflammatory bowel disease: A systematic review. Journal of Psychosomatic Research. 2016;87:70–80. - PubMed
-
- Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: A systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflammatory Bowel Diseases. 2016;22(3):752–762. - PubMed
-
- Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337. - PubMed
-
- van der Have M, van der Aalst KS, Kaptein AA, Leenders M, Siersema PD, Oldenburg B, Fidder HH. Determinants of health-related quality of life in Crohn's disease: A systematic review and meta-analysis. J Crohns Colitis. 2014;8(2):93–106. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
